- PRICING
- LIVE QUOTES
- LEARN
- HELP
EN
Why CareDx Stock Jumped Today
Key Points
CareDx is helping to improve outcomes for transplant patients.
The health monitor's non-invasive tests are in high demand.
Shares of CareDx (NASDAQ: CDNA) climbed on Friday after the precision medicine diagnostics specialist lifted its full-year sales and earnings forecast.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Healthy growth
CareDx's revenue surged 52% year over year to $132 million in the second quarter.
The healthcare company's non-invasive tests help doctors monitor the health of transplant patients. The Centers for Medicare & Medicaid Services (CMS) affirmed coverage for CareDx's surveillance testing for kidney, heart, and lung transplants earlier this month.
"Revenue growth reflected continued demand across transplant programs, favorable reimbursement dynamics, and increases in testing activity across both surveillance and for-cause settings," the company said in its earnings release.
All told, CareDx's adjusted net income more than tripled to $20 million, or $0.37 per share. That was well above Wall Street's estimates, which had called for per-share profits of $0.23.
Raised guidance
These robust results prompted CareDx to increase its full-year revenue outlook to $490 million to $500 million, up from a prior forecast of $447 million to $465 million.
Management also now projects adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $66 million to $78 million, up from $43 million to $57 million.
CareDx's recently completed acquisition of oncology diagnostics provider Naveris should help accelerate its expansion.
"We have transformed CareDx into a differentiated precision molecular diagnostics company with a unique set of core competencies that position us for continued profitable growth," CEO John Hanna said.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.